68,551 Shares in Boston Scientific Corporation $BSX Acquired by Osmosis Investment Management UK Ltd

Osmosis Investment Management UK Ltd acquired a new stake in shares of Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 68,551 shares of the medical equipment provider’s stock, valued at approximately $2,926,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. CYBER HORNET ETFs LLC increased its holdings in shares of Boston Scientific by 3.4% in the third quarter. CYBER HORNET ETFs LLC now owns 4,004 shares of the medical equipment provider’s stock valued at $391,000 after purchasing an additional 132 shares during the period. Gerber Kawasaki Wealth & Investment Management lifted its holdings in shares of Boston Scientific by 4.7% during the fourth quarter. Gerber Kawasaki Wealth & Investment Management now owns 3,082 shares of the medical equipment provider’s stock worth $294,000 after purchasing an additional 139 shares during the period. Northwestern Mutual Investment Management Company LLC lifted its holdings in shares of Boston Scientific by 0.3% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 47,366 shares of the medical equipment provider’s stock worth $4,516,000 after purchasing an additional 140 shares during the period. Kingsview Wealth Management LLC lifted its stake in Boston Scientific by 2.4% during the 4th quarter. Kingsview Wealth Management LLC now owns 6,066 shares of the medical equipment provider’s stock valued at $578,000 after acquiring an additional 142 shares during the period. Finally, Uptick Partners LLC increased its stake in shares of Boston Scientific by 5.6% in the fourth quarter. Uptick Partners LLC now owns 2,699 shares of the medical equipment provider’s stock worth $257,000 after acquiring an additional 143 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $60.00 target price on shares of Boston Scientific in a research report on Thursday, July 30th. Truist Financial cut their price target on Boston Scientific from $62.00 to $57.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. TD Cowen reduced their price objective on Boston Scientific from $61.00 to $56.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Raymond James Financial reissued an “outperform” rating and issued a $57.00 price objective on shares of Boston Scientific in a report on Thursday, July 30th. Finally, Needham & Company LLC lowered their target price on Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research note on Wednesday, July 8th. Twenty-four analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Boston Scientific currently has an average rating of “Moderate Buy” and an average price target of $71.62.

Boston Scientific Stock Up 0.0%

BSX stock opened at $50.39 on Monday. Boston Scientific Corporation has a one year low of $42.20 and a one year high of $109.50. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The firm’s fifty day moving average is $46.34 and its 200 day moving average is $57.62. The firm has a market cap of $73.03 billion, a PE ratio of 20.40, a P/E/G ratio of 1.10 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the prior year, the firm posted $0.75 earnings per share. The company’s revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, research analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific announced that its Board of Directors has initiated a stock buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney acquired 186,240 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was acquired at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the transaction, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David C. Habiger bought 2,100 shares of Boston Scientific stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the purchase, the director owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders have acquired 194,522 shares of company stock valued at $9,385,210. Company insiders own 0.34% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.